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ABSTRACT
For some time now, bioethicists have paid close
attention to issues associated with ‘enhancement’;
speciﬁcally, the appropriate use and regulation of
substances and artefacts understood by some to improve
the functioning of human bodies beyond that associated
with ‘normal’ function. Medical humanities scholars
(aside from philosophers and lawyers) and social
scientists have not been frequent participants in debates
around enhancement, but could shine a bright light on
the range of dilemmas and opportunities techniques of
enhancement are purported to introduce. In this paper,
we argue that empirical research into the notion and
practice of enhancement is necessary and timely. Such
work could fruitfully engage with—and further develop
—existing conceptual repertoires within the medical
humanities and social sciences in ways that would afford
beneﬁt to scholars in those disciplines. We maintain that
empirical engagements could also provide important
resources to bioethicists seeking to regulate new
enhancements in ways that are sensitive to societal
context and cultural difference. To this end, we outline
an empirical agenda for the medical humanities and
social sciences around enhancement, emphasising
especially how science and technology studies could
bring beneﬁts to—and be beneﬁtted by—research in
this area. We also use the example of (pharmaceutical)
cognitive enhancement to show how empirical studies of
actual and likely enhancement practices can nuance
resonant bioethical debates.
INTRODUCTION
Biomedical and technological developments,
regarded as having the capacity to improve the
body’s appearance or function, are often termed
‘enhancements’.1–3i Over the last 15 years or more,
bioethical and policy discourses have questioned
the appropriateness of enhancements for indivi-
duals and societies.4 5 Discussions have turned on
the problems of differentiating enhancement from
therapy, the hubris of changing nature and the
potential for exacerbating social inequalities. Such
questioning has resulted in sometimes acrimonious
debate playing out in journals, conferences and in
the meeting rooms of learned societies and policy
advisory committees—as well as in more public
arenas. These widely circulating questions and
concerns around enhancement are, no doubt,
important matters for consideration, but we believe
they are not the only issues of import. More needs
to be understood about the social, political and his-
torical contexts in which ‘enhancements’ arise, as
well as the reception and uptake of speciﬁc drugs
or devices.6–8 Further, the potential of new tech-
nologies to reconﬁgure health, medicine, social
relations and subjectivities is also relevant to bio-
ethical debate. Yet, if and when this complex issue
appears within bioethics discourse, it is often
theorised in isolation from other traditions that
have taken the relationships between materials,
bodies and societies to be key foci.
In this article, we suggest that the empirical
medical humanities and social sciences can contrib-
ute meaningfully to societal discourse around
enhancement in two key ways. First, and most
importantly, by attending to issues less commonly
considered in current debates. Second, by providing
methodologically robust studies of actual practices
involving technologies and chemicals regarded as
enhancing (which might intersect directly with—
and in some cases challenge—bioethical deliber-
ation).9 We take these matters in turn, with the ﬁrst
and substantive focus of this paper examining how
research foci within the medical humanities and
social sciences might (re)direct analytical attention
to the tools, bodies and institutions that populate
debates around enhancement. Then, we move to a
more speciﬁc account of ‘cognitive enhancement’
using pharmaceuticals meant for attention disor-
ders. These are employed as a case study of empir-
ical engagement with a matter of bioethical
concern, in order to consider the beneﬁts to bioeth-
ics that such analyses might afford. Debates around
drugs taken to have enhancing properties to the
human brain are wide-ranging; such pharmaceuti-
cals attract broad attention due to the wider social
and legal contexts of their use and the potential
implications for personal responsibility and liability
that come with this. An exploration of extant
studies is indicative of new empirical research tra-
jectories that might be considered, and the salience
of such scholarship for bioethical deliberation.
EXPLORING NEW TERRAIN
We outline some research questions and directions
that might contribute to research on enhancement
that intersects with existing bioethics scholarship.
As a consequence of our own inclination towards
the ﬁeld of science and technology studies (STS),
we start with specifying questions that direct the
gaze of scholars to the objects around which
Open Access
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iWe place the word ‘enhancement’ within quotes in order
to signal our reticence to ontologise particular tools and
substances as intrinsically ‘enhancing’ (or, indeed,
‘therapeutic’). Our reasons for this will become clearer as
the analysis unfolds.
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bioethical debate circulates (eg, pharmaceuticals), before consid-
ering the sociotechnical networks that enable, legitimise and
sustain their production and consumption.
Like others, we feel that the substantial body of interdisciplin-
ary STS scholarship on the social shaping of technology is of
immediate relevance and import to our considerations.2 6 8 10
Such work seeks to open up the ‘black box’ of technology and
consider the ways in which a range of social and economic
factors construct the eventual form and feel of an object. In the
case of enhancement, we might ask: what ideas about society, of
the body, and of individual hopes and fears are imagined and/or
channelled within processes of innovation? What values—clin-
ical, scientiﬁc, economic, societal and so on—are ‘inscribed’ in
particular substances and technologies deemed to be enhan-
cing?11 How are the practices of potential users conﬁgured in
the process?12 Scrutiny of the circulation and transformation of
different kinds of value and values within the innovation pro-
cesses producing technological enhancements will likely repre-
sent an interesting case for scholars who have attended to these
issues in more straightforwardly biomedical contexts (such as in
drug trials, trial recruitment and marketing).13 Disaggregating
the different values and practices of valuation constitutive of the
innovation and consumption of materials purchased (in formal,
grey or black markets) for their enhancing properties also serves
to trouble the more essentialist claims of some bioethical com-
mentators who present these as unproblematic social and indi-
vidual goods.3 6 8 10 14
Regulating biomedical lives
As a range of scholars have shown, economic value relates
closely to how any new tool, technology or drug is apprehended
by law, constituted through legal processes and regulated on the
market.15 Questions of law and regulation, then, are central to
innovation processes, both during development and after the
ﬁnished products are released. Recent work at the interface of
regulatory studies and STS has illustrated how particular modes
of governance are part of the societal context that can be built
into technologies, helping to shape their design and mode(s) of
delivery.16–18 Sheila Jasanoff, for example, uses cross-cultural
case study methods to demonstrate how political cultures affect
the way societies assess evidence, evaluate risk and engage with
publics around innovations in science and technology.19 Such
perspectives could contribute considerably to understanding the
differences regarding how policy issues around enhancements
are framed, as well as what—and whose—values become
embedded in the institutions governing their use.
Social histories of technologies are also often omitted from
studies of ‘enhancements’, but can be key to understanding the
interpretation of certain technologies. For example, the bur-
geoning science of optogenetics uses optics and gene modiﬁca-
tion techniques to control the activity of speciﬁc cells.ii In
addition to the promise of modulating cell function in neuro-
logical disorders, scientists suggest they can alter addictions,
depression and mood disorders and other behavioural and psy-
chosocial conditions. Previous controversies over gene therapy
and psychosurgery will surely colour how such emerging techni-
ques will be viewed from both regulatory and ethical perspec-
tives.20 21 Additionally, popular culture, including science ﬁction
themes of mind control, have been known to affect legal
frameworks in which such brain interventions would be viewed
for therapeutic purposes, much less enhanced function. There
has already been considerable scholarly interest in the interac-
tions of law and neuroscience, particularly in light of questions
of altered autonomy, identity, personal responsibility and liabil-
ity with the use of brain stimulation techniques.22–24
Accordingly, it will be fruitful to examine how legal processes
shape the production and deployment of tools and substances
that are understood to enhance human bodies and cognition.
This is in terms of how actual regulation directs innovation, and
if and how imaginaries of future governance inform the devel-
opment and marketing of objects framed as enhancements.
Court cases where these ﬁgure would likewise be important to
examine, in terms of how object ontologies (eg, purported
nature of particular drugs and devices, and hence, the ‘appropri-
ate’ uses to which they are put) and subjective properties
(eg, authenticity, personhood, etc.) are co-produced. It is also
important to attend to the ways that such innovations are situ-
ated within so-called knowledge-intensive societies, with their
emphasis on performance, productivity, competition and con-
nectivity. Markets are likely to help shape legal and regulatory
environments as much as the technologies themselves.
Documenting how ‘enhancements’ are dealt with in clinical
practice especially—including who is empowered to control
access to them, and why—will be a key empirical task for those
in the medical humanities and social sciences. Not enough is
known about how physicians represent to patients (and them-
selves consider) the beneﬁts, risks and harms of potentially
enhancing products and treatments, nor how ‘legitimate’ use is
conﬁgured.25 Further to reﬂecting on the philosophical or
policy implications of how products might be classiﬁed as thera-
peutic or enhancing, scholars might ask: what comes to count in
how health professionals (not solely medical practitioners)
decide whether the use of one particular drug or technology
counts as ‘therapy’ or as ‘enhancement’? For instance, do physi-
cians consider the moral or legal implications of prescribing
attention deﬁcit-hyperactivity disorder (ADHD) drugs for off-
label purposes, including enhancing cognition? To what extent
are they aware of how patients may be using such prescribed
drugs, including selling them to others?26 The literature on
ethical decision-making in clinical practice will afford beneﬁt to
empirical analysis of such questions, which will in turn enrich
scholarship around ethics-in-practice.27 28
Ethnographic and conversation analytic work might usefully
examine the physician–patient dance involved in representing a
subjective state as a legitimate target of optimisation, not least to
cast further light on the cultural logics shaping discourses of
legitimacy today.29 In cases where physicians may be reluctant
to prescribe ‘enhancements’ to individuals who ask for them,
where do individuals who wish to consume these then turn?
Research exploring such issues may have much to offer socio-
legal studies in terms of understanding how grey markets are
formed and negotiated by a range of individuals. Further, inter-
views and other methodological strategies might be employed to
examine how users construct the beneﬁts, risks and harms of
substances and tools used to enhance human bodies (in particu-
lar, where access is achieved beyond the clinic, such as via the
internet). Users may employ these notions in ways that are quite
distinct from those featuring within biomedical and bioethical
discourses, and the regulatory regimes that are in part consti-
tuted through these (as we will show below—drawing on
a range of work—for the case of cognitive enhancement).8
For example, comparative work between prescription and
non-prescription ‘enhancements’ (such as the use of nicotine
iiSpeciﬁcally, light-responsive DNA segments are inserted into cells and
when externally activated by a light source, can be switched on or off to
observe effects in living subjects, or modulate cell function.
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replacement patches as stimulants) regarding publics’ construc-
tions of risk would be both timely and have import for scholarly
interrogations of the production of risk, harm and safety in
other (non-)medical domains. Since public engagement plays an
important role in in shaping policy approaches to new and
emerging technologies, consideration will be required of how
this is leveraged as a regulatory device to either promote or
curtail the use of supposed enhancements.30
Relatedly, more critical work might document the establish-
ment of new professional networks (both formal and informal)
of scientists and ethicists (such as the International Neuroethics
Society), and the ways in which calls for regulation and ethical
oversight can function as a means of rendering particular socio-
technical pathways legitimate.31 The legitimating function of
bioethics has been analysed for ‘therapies’ rather than ‘enhance-
ments’ (eg, using the case of pharmacogenetics), but any impact
of (inter)national ethics bodies—if it exists—on the consump-
tion of products that can be used to enhance bodily or cognitive
function has not been formally examined.32 Further, we might
also explore the degree to which the act of calling out issues of
bioethical or regulatory concern can be employed as a vehicle
for establishing organisational authority and legitimacy. In par-
ticular, under the Bush administration in the USA, the
President’s Council on Bioethics garnered considerable attention
through bioethical agenda-setting and what some regard as over-
cautionary reports, including on enhancement.33 Both historical
and ethnographic research could reveal how and to what extent
ethical claims-making and organisational legitimacy relate to
each other. Such scholarship could engage productively with
feminist bioethics; this has cast a critical eye upon issues of
authority and legitimacy, and renders problematic the universal
subject that is often assumed by ofﬁcial ethics bodies. Rhetorical
analyses of formal reports, documents and position papers
deployed by such organisations will also illuminate embedded
political rationalities (E Barr. The President’s Council on
Bioethics’ ‘Happy Souls’: discipline, citizenship and true selves,
unpublished manuscript, 2014).
Diverse bodies
Above we noted some of the diverse kinds of empirical attention
that could be paid to the development, production and market-
ing of technologies and pharmaceuticals characterised in various
spheres as enhancements. Cutting across this must also be an
analytic sensitivity to the ways through which the intertwined
issues of gender, ethnicity, sexuality, sociodemographic status
and other markers of identity are implicated in practices of
innovation and consumption.34 How are particular ideas of
gender, for instance, embedded within enhancements, and how
are new drugs and technologies gendered within media and
marketing portrayals (and, indeed, within academic writing)?
How do they impact on experienced and ascribed gender?
Viagra is perhaps the case per excellence here, and empirical,
STS-inﬂected research on this has cast bright light on its gen-
dered marketing and uptake—but also on sites of resistance, and
communities of users (eg, women) who have appropriated this
drug and re-inscribed its embedded scripts so as to situate it
within new regimes of personal life.35 Likewise, painkillers have
been used in Indonesia to enhance libido, and hormonal therap-
ies have been documented as being repurposed by individuals
self-identifying as men who seek to feminise their bodies.36
Research in this vein reveals the complex social lives of
‘enhancements’ that exceed anticipatory imaginaries of their
uses and actions, and that also enrich medical humanities and
social scientiﬁc understandings of the relationships between bio-
medicine and wider society.37
A concern with gender—as well as ethnicity and other
somatic markers of identity—connects with themes of embodi-
ment more generally. Debates in this area might stimulate a con-
sideration of any changes to how bodies ‘dys-appear’ (ie, come
to subjective attention through pain, disability or impairment),
disappear and reappear in societal practices and discourses asso-
ciated with the drugs and technologies that some deem to
enhance human traits and states.38 What aspects of ‘normal’
bodies could come to be regarded as sites of intervention in
contexts where diverse forms of customisation are possible? The
use of human growth hormone to simultaneously ‘treat’ and
‘enhance’ height is one example where the differences between
‘therapy’ and ‘enhancement’ emerge as complex, contingent
and readily reworkable. With a focus on the ‘treatment’ of short
boys, such distinctions are also highly gendered.39 Further, the
human brain seems often to only become salient in personal dis-
course through its dys-appearance due to injury or cognitive
impairment—yet, in an era of proliferating enhancements, it
may increasingly be viewed as a plastic organ operable upon
through techniques of ‘objective self-fashioning’ via pharmaceu-
ticals or electroceuticals.40–43
At the same time, ‘dys-appearing’ forms of (especially) neuro-
logical difference are increasingly subject to projects of
de-stigmatisation (eg, in the case of autism).44 In this light,
understandings of techniques that operate upon human differ-
ence (be those drugs, devices or psychological interventions)
can shift from being conceptualised as part of a therapy-
enhancement continuum to being questioned over whether they
are unwanted (and perhaps even coercive) tools of normalisa-
tion. The use of enhancements therefore represents the opening
up of a new set of cases for empirical examination both in terms
of how ‘differences’ between humans come to be recognised as
such, and of how much difference populations are prepared to
accept. Historians, anthropologists, geographers and others are
particularly well placed to parse out how the uses of enhance-
ment technologies might recast what bodily properties are taken
as valued in particular contexts, by who and to what ends, and
how the practices and consequences of valuation interact with
actual engagements with enhancing technologies.45 A reinvigor-
ation of research around cosmetic surgery is one starting point
for the interrogation of these questions, especially including
non-Western spaces and places where empirical ethnographic
research might render problematic any assumptions that emerge
regarding such practices based on their contemporary uses in
Europe and North America.46 In Brazil, for example, the experi-
mental use of testosterone to enhance vigour and verve means
that there is no ready place to position this along any kind of
linear ‘therapy’/‘enhancement’ continuum.47 Rather, as Alex
Edmonds puts it, ‘health and aesthetics become entangled’.48
Cross-cultural empirical research could further illustrate (and
perhaps contribute to the destabilisation of) Anglo-American
societal norms that assume what counts as ‘therapy’ and what
comprises ‘enhancement’ (simultaneously decentring ‘the West’
within bioethical analyses in this area).
Constructing communities and contexts
Thinking about changing cross-cultural experiences and iden-
tities also directs our attention to the formation of new social
groups orientated around apparent enhancements. Debates
around the uses to which objects deemed enhancing might be
put have helped to stimulate a range of neologisms (such as ‘bio-
conservative’ and ‘transhumanist’) that will be of interest to
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researchers keen to document, explore and understand how
these become an idiom through which communities coalesce
and expand. There are identity politics at play that are import-
ant to attend to: different communities can and could respond
to discourses and practices centring on drugs and devices asso-
ciated with human enhancement in diverse ways that speak to
broader (and diverging) conceptions of humanity, sociality and
public good.49 Disability studies scholars have begun to unpick
some of the wider moral and political dimensions and implica-
tions of the imaginaries fuelling the speculation and advocacy of
self-identifying ‘transhumanists’ (individuals who propose wide-
spread adoption of a range of radical enhancements), for
example. Their concerns regarding new forms of discrimination
are suggestive of the need for empirical work with normative
bite.50 Further, philosopher Trijsje-Marie Franssen has examined
how the myth of Prometheus features within and conﬁgures
debates around human enhancement and transhumanism (T-M
Franssen. Prometheus through the ages: from ancient trickster
to future human. University of Exeter: Unpublished doctoral
thesis 2014. Available at: https://ore.exeter.ac.uk/repository/
bitstream/handle/10871/15889/FranssenT.pdf?sequence=1).
Scholarship of this kind provides insight into how images and
imaginaries come to be instantiated within the identities of
novel communities, and the discussions about medical technolo-
gies that these in turn propel.
A further point of departure for empirical work around the
broad issue of ‘enhancement’ might be to interrogate how
ethical debates and social practices (including but not limited to
processes of innovation) mutually shape one another.51 The
co-productionist tradition of STS—which foregrounds the dyna-
mism between materiality and sociality—could provide rich con-
ceptual resources for consideration of the reciprocal constitution
of objects, moral discourse and social practices.52
Co-productionist studies of enhancement might also attend to
how any routine use of enhancements could change their cul-
tural contexts. How, for instance, does the promotion and use
of particular technologies—such as drugs to enhance cognition
—respond to issues of social concern (eg, educational attain-
ment)? In turn: how, and to what extent, does the embedding of
enhancements within societies recast the meanings of the terms
by which societal issues are debated? Engagement with such a
question necessarily entails an historical, rhetorical and ethno-
graphic analysis of what ‘individual attainment’ is taken to be
within speciﬁed cultures, and what cultural actors judge to be
legitimate means of performing accomplishments. Accordingly,
research that takes the practices of and politics around enhance-
ment as a starting point could produce textured and nuanced
scholarship that contributes to conceptual and empirical litera-
tures far beyond the case study under primary examination.
Finally, a co-productionist perspective also enjoins us to
engage with the emergence of the debate around ‘therapy’ and
‘enhancement’ itself. As indicated above, we argue that these
concepts come to ﬁnd meaning through particular conﬁgura-
tions of social conventions, epistemic norms and biomedical
tools. Intrinsically normative characterisations, their position in
relation to each other is ambiguous and ever-changing, since the
terrains of treatment and of enhancement have boundaries that
shift according to mutations in the same sociotechnical practices
that constitute them.6 10 The ﬂexibility of these spaces under-
scores what we regard as a central problem for medical human-
ities and social science scholars: how, why and where do
particular technologies come to count as ‘enhancing’? Since the
categories of ‘therapy’ and ‘enhancement’ are emergent through
social praxis, any deﬁnitional settlements are of course
essentially contingent, yet historical, geographical and anthropo-
logical research tracing processes of stabilisation is both timely
and important.
EMPIRICAL ANALYSES OF PHARMACEUTICAL COGNITIVE
ENHANCEMENT
Throughout our analysis, we have sought to take care over how
we use the term ‘enhancement’, indicating what empirical
research agendas might be propelled through an acknowledge-
ment that there are a number of individuals and groups who
actively use this word and ascribe it to actual or imagined
objects around which social practices are orientated—as well as
many more people who (seek to) ‘enhance’ their bodies and
brains in the absence of this idiom. In addition to being of
import for the wider medical humanities and social sciences, we
believe (and in so doing take cues from scholars such as Adam
Hedgecoe) that empirical attention to the discourses and objects
associated with enhancement might also better ground bio-
ethical claims and appraisals in this area.9 Given that qualitative
and quantitative methods have become more common in bioeth-
ics, we suggest that these methods can help to illuminate how
ethically signiﬁcant issues related to enhancement play out in
everyday life.53 Practices of enhancing cognition, for example,
have been central to much of the bioethical discussion that
focuses explicitly on enhancement, especially the use of pharma-
ceuticals that promote concentration and alertness (for instance,
brand names Adderall and Ritalin). Bioethicists of a more liber-
tarian bent argue that such drugs should be more widely and
freely available to those who want them, and that potentially
citizens have a duty to consume them.14 Arguments like these
can be seen as situated within a broader discourse of what social
scientists have referred to as ‘biological citizenship’—the implicit
or explicit connection of citizenship to somatic states or
processes.54
Work is being produced that is seeking to quantify the degree
to which drugs like Adderall are being used (eg, by university
students).55–57 Interview studies are concerning themselves with
the texture of this use and the meanings that are ascribed to
it.26 58–61 Notably, for instance, a recent paper by Singh et al57
underscored that many UK students were not familiar with cog-
nitive enhancement. Such scholarship is needed in order to
ensure that bioethical analysis is grounded in what seems to
actually be happening in schools, workplaces and in the home—
and what feasibly, based on empirical research on current prac-
tice, could start to happen.7 This is in contrast to a common
bioethical focus on more speculative matters, and by commenta-
tors who may be geographically, professionally and personally
distant from the ﬁgures that populate their imaginaries.
One useful resource is Catherine Coveney’s sociological study
of a range of individuals (including university students, health
professionals and other shift workers) asked to envision the use
of a drug promoting wakefulness (speciﬁcally, modaﬁnil; brand
name: Provigil).6 7 Her ﬁndings showed that potential uses of
this enhancement included ensuring safety at work (eg, amelior-
ating the dangers posed by sleepy surgeons), but also as a study
aid. However, perceptions both of legitimate use and the legit-
imacy of the drug per se were tightly interwoven with its legal-
ity, and how readily available it was (eg, from local pharmacists,
without a prescription, or from physicians only).62 Accordingly,
what Coveney’s research shows is that public attitudes towards
enhancement drugs are linked to broader feelings towards phar-
maceuticals more generally—and, speciﬁcally, the ways in which
(to borrow historian Keith Wailoo’s term) the ‘identities’ of
drugs are constituted through regulatory regimes.63 64 This
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insight has salience for bioethical debate that might take the
meanings of pharmaceuticals to be solely a function of personal
mores, as opposed to being powerfully shaped by the social fra-
meworks in which they and their consumers are embedded.65–67
Other work by social psychologist Ilina Singh directs attention
to the actual users of pharmaceuticals. One major theme around
cognitive enhancement is ‘authenticity’, and bioethical scholar-
ship focusing on this has until recently operated rather tangen-
tially from empirical research. Questions discussed within the
bioethics literature include what it might mean to live authentic-
ally, whether regular pharmaceutical use necessarily results in an
‘inauthentic’ life and if medication can in itself enhance authen-
ticity. Conclusions may seek to direct the use of enhancements,
including both restrictions and expansions of access to these
drugs and technologies.68 A major contribution from Singh is
her qualitative work with children diagnosed with ADHD, in
which discussions took place around the relationship between
psychopharmaceutical consumption and understandings of
authenticity.69 70 For this work, Singh interviewed more than
150 children between 9 and 15 in both the USA and UK. As she
shows, drugs are not viewed as necessarily challenging or com-
promising characteristics associated in the bioethics literature
with authenticity, and in some cases are ﬁgured by children as
supporting, for instance, moral agency.70 This is suggestive of
the degree to which the use of psychopharmaceuticals that act
on cognition by consumers who do not have a psychiatric diag-
nosis may also refrain from seeing the use of Adderall or Ritalin
as compromising their autonomy. There are implications here
for bioethical debates around whether individuals should imbibe
these substances in order to preserve their authenticity.
Empirical work on authenticity potentially is of interest to phi-
losophers concerned more directly with this concept per se.
Perspectives from users of ‘enhancements’ have also been the
focus of sociologist Scott Vrecko’s research.26 61 His partici-
pants were university students at a US institution who used
Adderall and Ritalin as study aids. Vrecko asked young men and
women about their experiences of consuming such drugs, and
elicited striking narratives of their practices. In particular, he
revealed the diverse kinds of illicit exchanges through which
prescription drugs come to be used for non-prescribed pur-
poses, as well as the highly emotional impact of drug effects,
whereby his respondents detailed how it felt to be ‘on’ psycho-
pharmaceuticals that were understood by them to improve their
work. Students discussed feelings of channelled interest and
enjoyment (ie, a tight focus on, and pleasure in, the studies they
were immediately employed in and not other things happening
around them), ‘drivenness’, and feeling mentally and/or physic-
ally ‘up’.61 Such ﬁndings resonate with the more recent research
of Margit Anne Petersen and colleagues, who likewise have
underscored the role of prescription stimulants in sharpening
students’ focus on their work, as well as on the subjective
experience of work per se (and also on the moral ambivalences
that characterise drug use in this context).59 60 These experi-
ences challenge the more ‘unemotional’ (as Vrecko puts it),
sometimes strongly rationalist, accounts of decision-making and
use that have found a home within much bioethical deliberation
on cognitive enhancement. Hence, Vrecko’s and Petersen et al’s
ﬁndings are suggestive of the need to bring in the perspectives
of actual users into the discursive spheres of bioethical and
policy deliberation.
Work such as that summarised above thus complicates bio-
ethical claims-making by underscoring the ways in which mul-
tiple meanings adhere to substances. As Coveney, Singh, Vrecko,
Petersen and others remind us, drugs are never just their
chemical constituents. Rather, they may take on a variety of
‘identities’ (and have different effects) depending on the context
within which they are (or realistically might be) used. Many
standard analyses of risk and beneﬁts of pharmaceutical means
of enhancing cognition take for granted what a drug ‘really’ is;
that is, they are concerned solely with its active ingredients,
mode of biological action and physiological effects. In so doing,
commentaries and appraisals can elide the diverse and shifting
societal understandings of the nature of the substance in ques-
tion.6 8 Besides holding science and society as separate domains,
in these cases recommendations for policy and practice can be
problematic as they might lack social salience. If a culturally
impoverished understanding of a drug is mobilised in debate,
the complexities of deciding whether or not this substance can,
should or must be used are obfuscated, and so the legitimacy
and utility of any conclusions reached are lessened. Our point is
one that will be familiar to scholars concerned with the social
lives of pharmaceuticals: that understandings of drugs and their
effects are mediated through their use, the context of this, and
who drugs are being used by and for what reasons. This illus-
trates the necessity of the empirical studies of enhancement
already being undertaken. Further, it suggests the need for more
in-depth quantitative, qualitative and interpretive research
(informed by relevant theoretical and conceptual literatures
from the medical humanities and social sciences) that can
attend more precisely to the contextual issues we believe are
so necessary to integrate into bioethical deliberation, and
which have begun to be charted by the authors discussed
above.2 3 10 29 71 72
CONCLUSION
Our aim in this analysis has been twofold. First, and most
importantly, in common with scholars like Coveney, Morrison,
Singh and Vrecko, we want to more ﬁrmly ﬁx the attention of
the empirical medical humanities and social sciences to the
objects, bodies, subjectivities and discourses that populate
debates around the enhancement of human bodies and minds.
Our hope is that this can be achieved in ways that are not dis-
missive of traditional normative analysis or the debates around
autonomy and responsibility that are so prevalent within bioeth-
ics, but which nevertheless uncover new territory for empirical
exploration and theorisation. Indeed, perspectives from the
wider medical humanities and social sciences can, we believe,
also be brought to question the very terms through which
bioethicists, policymakers, entrepreneurs and others are cur-
rently framing and advocating their positions and movements
(eg, as enhancement ‘bioconservatives’ or proponents).
Examining substances and devices that some regard as having
the capacity to enhance human bodies and cognition can inform
our understandings of the interactions between biomedicine and
society more broadly, and hence, represent important case
studies for scholars in cultural studies, history, law and STS, to
name just a few disciplines.
Second, in mapping the terrain that the empirical medical
humanities and social sciences might chart (and, indeed, have
begun to explore), we want to make a renewed call for the
importance of drawing the expertise of these scholars into the
spheres of policy-orientated bioethical decision-making (and
potentially disrupt them). We recognise the quality and rigour
of many contributions from philosophers and others to under-
standings of enhancements in society; nevertheless, we suggest
that a still more nuanced understanding of these issues, incorp-
orating (or at least, drawing on) the expertise of other human-
ities scholars and of social scientists, might further enrich
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bioethical discussions. We believe that the appraisal and analysis
of any new sociotechnical practices associated with enhancing
human capabilities must be constituted through sensitivity to
the larger historical, cultural and political context within which
they ﬁnd form—and likewise should be sensitive to how tech-
nologies of enhancement might reconﬁgure those con-
texts.3 6 8 10 73 Key here is research that engages a range of
publics with decision-making around enhancements.74 75 In so
doing, there is an increased likelihood that recommendations
can be reached which resonate with the lived experiences of pol-
icymakers, scientists, clinicians, patients and a range of other
users. Accordingly, workable solutions to the governance of con-
tested drugs and devices associated with enhancement might
more readily be achieved.
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